Clinical trial
A Phase 2, Open-label, Study to Evaluate the Safety and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV, MVA-BN-Filo in Adults and Children Originally Enrolled in the Control Arm of the EBOVAC-Salone Study
NCT05284097 is registered in ClinicalTrials.gov with London School of Hygiene and Tropical Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Study to Evaluate the Safety and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV, MVA-BN-Filo in Adults and Children Originally Enrolled in the Control Arm of the EBOVAC-Salone Study
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 19, 2022
- Completion date
- October 31, 2024
- Enrollment
- 133 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ebola, filoviridae infections, hemorrhagic fever, ebola, hemorrhagic fevers, viral, immunologic factors, infections, mononegavirales infections, physiological effects of drugs, rna virus infections, vaccines, virus diseases